A May 2025 systematic review identified 11 clinical studies (including 2 RCTs) on exosome-based hair-loss interventions; one registered RCT (NCT06932393) was terminated in May 2026 due to the trial site's regulatory ineligibility.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Early clinical
How it works
Extracellular vesicles ('exosomes') secreted by stem cells (often hair-follicle or other mesenchymal stem cells), injected into the scalp to deliver growth-promoting signals to miniaturized follicles.
Results so far
Across reviewed studies, hair count improvements ranged from 9.5 to 35 new hairs/cm2 and hair thickness improved by up to 13 micrometers after 1-2 sessions, with no serious adverse effects reported — but the review explicitly calls for larger, better-designed trials before broad clinical adoption.
What's next
No regulatory approval pathway established; this remains a procedure offered off-label/as an aesthetic service in many markets rather than an approved drug.
In India
Not specifically assessed; exosome/PRP-adjacent treatments are known to be offered in some Indian hair clinics commercially, but no Indian trial or regulatory status was verified in this research pass.
Sources
- Journal paper ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.